Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Research

Mineralys Therapeutics
Regional / Research

Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial

November 3, 2026November 1, 2026 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat significantly reduced blood pressure and urinary protein levels in patients with chronic kidney disease, according …

Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial Read More

Aclaris Therapeutics
Research

Aclaris Prioritizes Esophageal Drug Trial After Early Results

November 2, 2026November 1, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) plans to advance its experimental antibody ATI-052 into a Phase 2b trial for eosinophilic esophagitis in early 2027, concentrating development spending on …

Aclaris Prioritizes Esophageal Drug Trial After Early Results Read More
AstraZeneca
Regional / Research

AstraZeneca, Amgen Report Phase III Success for TEZSPIRE

October 29, 2026October 27, 2026 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca and Amgen reported that their immunotherapy TEZSPIRE significantly reduced esophageal inflammation and swallowing difficulties in a Phase III clinical trial, strengthening the companies’ case for expanding …

AstraZeneca, Amgen Report Phase III Success for TEZSPIRE Read More

Johnson & Johnson
Regional / Research

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks

October 28, 2026October 26, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved fistula remission through 48 weeks in a Phase 3 clinical trial, …

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks Read More
Annovis Bio
Research

Annovis Targets 2027 Alzheimer’s Drug Data Readout

October 28, 2026October 26, 2026 - by Timothy Alexander

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will present updates on its experimental Alzheimer’s disease treatment buntanetap at a November medical conference in Boston as the Malvern-based biotechnology company …

Annovis Targets 2027 Alzheimer’s Drug Data Readout Read More

ArriVent BioPharma
Regional / Research

ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial

October 26, 2026October 25, 2026 - by Timothy Alexander

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …

ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More
Teleflex Incorporated
Research

Teleflex Completes Enrollment in Coronary Scaffold Trial

October 24, 2026October 24, 2026 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has completed enrollment of 102 patients in a European clinical study evaluating longer versions of its dissolvable magnesium coronary scaffold, advancing research into …

Teleflex Completes Enrollment in Coronary Scaffold Trial Read More

Prelude Therapeutics
Regional / Research

Prelude Partners With Lilly to Test Breast Cancer Drug Combinations

October 19, 2026October 19, 2026 - by Timothy Alexander

WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) has entered a clinical trial collaboration with Eli Lilly and Co. to evaluate an experimental breast cancer treatment alongside two Lilly drugs, …

Prelude Partners With Lilly to Test Breast Cancer Drug Combinations Read More
ArriVent BioPharma
Regional / Research

ArriVent Advances Cancer Drug Pipeline With First U.S. Trial

October 19, 2026October 19, 2026 - by Timothy Alexander

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and …

ArriVent Advances Cancer Drug Pipeline With First U.S. Trial Read More
Johnson & Johnson
Regional / Research

Johnson & Johnson Reports Sustained Psoriasis Drug Response

October 17, 2026October 15, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis treatment ICOTYDE maintained clear or almost clear skin through two …

Johnson & Johnson Reports Sustained Psoriasis Drug Response Read More

Posts pagination

1 2 … 13 Next

Trending News

  • Four Suspects Sought in West Chester Assault Investigation

  • VA Awards Record $106.5 Million for Veterans Cemeteries

  • ICYMI: FDA Clears First DNA Immunotherapy for Rare Airway Disease

  • Palvella Wins Priority FDA Review for Rare Disease Drug

  • BLAST Robotics Caps Rookie Season With HAVOC Playoff Run

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Assault Investigation

Four Suspects Sought in West Chester Assault Investigation

November 3, 2026November 3, 2026

cemetery

VA Awards Record $106.5 Million for Veterans Cemeteries

November 3, 2026November 2, 2026

Federal Bureau of Investigation (FBI)

FBI Investigates Suspicious Mail Ballot in Chester County

November 1, 2026November 1, 2026

Copyright © 2026 MyChesCo.